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Abstract
Methamphetamine (MA) use is associated with activation of microglia and, at high doses, can induce neurotoxicity.
Given the changes in the neuroinflammatory environment associated with MA, we investigated whether MA
administration would interfere with the thermoregulatory and neuroinflammatory response to a subsequent per-
ipheral immune stimulus. C57BL6/J mice were given four i.p. injections of either 5 mg/kg MA or saline at two hour
intervals. Twenty-four hours following the first MA injection, mice were given 100 μg/kg LPS or saline i.p. and
blood and brains were collected. Here we report that mice exposed to MA developed higher fevers in response to
LPS than did those given LPS alone. MA also exacerbated the LPS-induced increase in central cytokine mRNA. MA
alone increased microglial Iba1 expression and expression was further increased when mice were exposed to both
MA and LPS, suggesting that MA not only activated microglia but also influenced their response to a peripheral
immune stimulus. Taken together, these data show that MA administration exacerbates the normal central immune
response, most likely by altering microglia.
Background
Methamphetamine is a popular drug of abuse that has
several central effects and is associated with an
increased prevalence of HIV infection, hepatitis B and
C, fungal infections, and possibly others [1-4]. Given the
popularity of MA, it is becoming increasingly important
to understand the effects of MA use on host responses.
Among some of its detrimental effects, MA exposure
has been associated with oxidative stress and the pro-
duction of reactive oxygen and nitrogen species [5,6],
neurotoxicity [7,8], and an increase in microglial activa-
tion and astrocytes, leading to the production of proin-
flammatory cytokines [9,10]. Long-term MA users show
prominent microglial activation in certain brain regions
that are sometimes apparent almost 2 years after MA
use had ceased [9]. MA-induced microglial activation
has also been shown in animals given high doses of MA
[11-13] and there is evidence that this activation
remains apparent up to seven days after treatment [10].
Both high and low doses of MA can induce inflamma-
tory cytokines such as tumor necrosis factor a (TNFa),
interleukin-1b (IL-1b), and IL-6 in the brains of rodents
[14-17]. Indeed, high-dose MA administration increased
TNFa protein in the straitum three days after treatment
[18] and in the hippocampus seven days after treatment
[10].
Peripherally, acute and chronic MA administration
have been shown to reduce the number of leukocytes as
well as NK cell activity of splenic lymphocytes [19].
Chronic MA administration reduced Con A-induced
T-cell proliferation as well as IL-2 and IFNg production
in mouse splenocytes [20], and a binge dosing regimen
suppressed the peripheral immune response to fungal
infection [21]. MA has also been shown to decrease IL-1
production by splenocytes in mice [22] and reduce IFNg
and IL-10 while increasing IL-4, MCP-1, and TNFa in
plasma [12]. Taken together, these data suggest that
MA alters the production of both inflammatory and
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anti-inflammatory cytokines in the periphery while indu-
cing a heightened inflammatory environment in the
brain. This MA-induced increase in brain inflammation
has the potential to influence the body’s response to a
subsequent immune stimulus.
While there are many studies concerning the conse-
quences of MA use alone, little is known concerning the
neuroinflammatory consequences of MA use and subse-
quent peripheral immune stimulation. Infection in the
periphery results in the production of inflammatory
cytokines which, through neural and humoral pathways,
induce glial cells in discrete brain regions to produce
the same inflammatory cytokines [23,24]. It is this cen-
tral production of inflammatory cytokines that is
responsible for inducing sickness behavior including
fever, anorexia, as well as reduced locomotor and social
behaviors. Excessive production of inflammatory cyto-
kines has been shown to produce severe behavioral
deficits and promote neurotoxicity [25]. Thus, circum-
stances that enhance inflammatory cytokine production
by microglial cells, such as MA use, are likely to lead to
pronounced and prolonged behavioral deficits that are
not conducive to health and recovery.
We have previously shown that repeated administra-
tion of low-dose MA attenuated both the febrile and
neuroinflammatory response to a subsequent injection
of lipopolysaccharide (LPS) in mice [26]. The attenuated
response appeared to be related to a MA-associated
alteration in the microglial response. Mice exposed to
five days of consecutive low-dose MA administration
showed decreased microglial activation when given a
subsequent injection of LPS compared to mice given
LPS alone. Given this decreased microglial activity, we
concluded that the MA-induced attenuation of the feb-
rile and neuroinflammatory response was due to an
inability of microglia to respond to LPS. Because of this,
the present study utilized a MA administration schedule
expected to activate microglia [7,13]. We hypothesized
that this MA schedule would activate microglia and
exacerbate the sickness and neuroinflammatory response
to LPS. Here we report that exposure to MA enhances
the LPS-induced fever response that is paralleled by
increased microglial staining and a dramatic increase in
inflammatory cytokine mRNA expression in the brain.
Methods
Animals and surgery
Adult (3-5 mo) male C57BL/6 mice from The Jackson
Laboratories were used. Mice were housed in polypropy-
lene cages and maintained at 23°C under a diurnal 12 h
light-dark cycle (lights on at 0700) with ad libitum access
to water and rodent chow. To allow for continuous moni-
toring of body temperature (Tb) and locomotor activity,
mice were anesthetized with an intraperitoneal (i.p.)
injection of ketamine and xylazine (100 and 10 mg, respec-
tively) and implanted with a biotelemetry device (E-mitter,
Mini Mitter, Bend, OR). Briefly, a midline abdominal inci-
sion was made 1 cm below the diaphragm and the E-mit-
ter was positioned in the abdominal cavity along the
sagittal plane. The muscle wall was sutured with chromic
gut and the skin sutured with silk surgical thread. Follow-
ing surgery, mice were individually housed and each cage
was placed on a receiver board (model ER-4000 Receiver,
Mini Mitter). Data was collected every 5 min utilizing the
Vital View data acquisition system (Mini Mitter Co., Bend,
OR). Tb and locomotor activity were monitored from the
time of implantation until the end of the experiment. Mice
were allowed at least 7 days to recover from surgery before
any experimental procedures took place. All procedures
were in accordance with the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals
and were approved by the University of Illinois Institu-
tional Animal Care and Use Committee.
Drugs
MA [(+)-Methamphetamine hydrochloride (Sigma, Cat #
M-8750)] was dissolved in sterile saline and injected i.p.
at a dose of 5 mg MA·HCl/kg body weight, four times
at 2 h intervals. This dosing schedule was based on
reports by Thomas and Khun [7,13] that showed the
schedule induced microglial activation. Escherichia coli
LPS (serotype 0127:B8, Sigma) was dissolved in sterile
saline and injected i.p. at 100 μg/kg body weight, a dose
that reliably causes fever in mice. Both MA and LPS
were diluted such that each dose was equivalent to an
injection volume of 0.01 mg/g. Control mice received an
equivalent volume of saline.
Experimental design
MA and LPS
To investigate if MA administration affects the inflam-
matory response to peripheral immune activation, mice
received four i.p. injections of either 5 mg/kg MA or
saline at 2 h intervals. Twenty-four hours after the first
MA injection, mice received i.p. injections of either LPS
(100 μg/kg) or saline and Tb and locomotor activity
were monitored for the next 24 h. Mice were then killed
by CO2 asphyxiation and blood and brains were col-
lected for cytokine measurement. To measure cytokines
at a time point when mice were actively sick, a separate
group of mice not implanted with E-mitters was sub-
jected to the same experimental protocol and killed at
4 h post-LPS.
Cytokine mRNA measurement by quantitative real-time
PCR
Total hypothalamic RNA was isolated using the Arc-
turus PicoPure™RNA isolation kit as described by the
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manufacturer. DNase treatment was performed on a
PicoPure column with a Qiagen RNase-free DNase set
(Qiagen, Valenica, CA). RNA from all other regions was
isolated using the Tri Reagent protocol (Sigma, St.
Louis, MO). A QuantiTect Reverse Transcription Kit
(Qiagen, Valencia, CA) was used for cDNA synthesis
with integrated removal of genomic DNA contamination
according to the manufacturer’s protocol and previously
described [26]. Quantitative real-time PCR was per-
formed using the Applied Biosystems (Foster, CA)
Assay-on Demand Gene Expression protocol as pre-
viously described [26]. In brief, cDNA was amplified by
PCR where a target cDNA (IL-6, Mm00446190_m1; IL-
1b, Mm00434228_m1; TNFa, Mm00443258_m1; and
CD68, Mn00839636_gl) and a reference cDNA (glucose-
3 phosphate dehydrogenase, Mm99999915_g1) were
amplified simultaneously using an oligonucleotide probe
with a 5’ fluorescent reporter dye (6-FAM) and a 3’
quencher dye (NFQ). PCR reactions were performed in
triplicate under the following conditions: 50°C for 2
min, 95°C for 10 min, followed by 40 cycles of 95°C for
15 sec, and 60°C for 1 min. Fluorescence was deter-
mined on an ABI PRISM 7900HT-sequence detection
system (Perkin Elmer, Forest City, CA). Data were ana-
lyzed using the comparative threshold cycle (Ct)
method, and results are expressed as fold difference.
Plasma cytokines
Plasma samples were assayed for IL-1b, TNFa, IL-6, and
IL-10 using a multiplex bead-based immunoassay kit
combined with a Cytokine Reagent kit as described by
the manufacturer (Bio-Rad, Hercules, CA). The multi-
plex assay was sensitive to <3 pg/ml for IL-1b, TNFa,
IL-10, and IL-6. The inter-assay and intra-assay coeffi-
cients of variation were <8%.
Immunohistochemical staining and quantification
A separate group of mice was exposed to the MA regi-
men and then given either 100 μg/kg of LPS or saline.
Four hours after i.p. injection of LPS, mice were killed
by CO2 asphyxiation and transcardially perfused with
heparinized saline followed by 4% paraformaldehyde,
and brains were removed. Brains were blocked in 3
parts (rostral, mid and caudal), postfixed over 2 days in
4% paraformaldehyde, and paraffin embedded. Coronal
sections (4 μm) were cut on a microtome and every 10th
section was stained for Iba1 (ionized calcium binding
adapter molecule 1; Wako Chemicals USA, Richmond,
VA) at the level of the striatum (Bregma -0.82 mm) and
at the hippocampus (Bregma -2.18 mm). Sections were
dewaxed and rehydrated through xylene and alcohols
and were incubated in citrate buffer, pH 6, and micro-
waved for 10 min. Endogenous peroxidase was elimi-
nated by incubating sections in 3% H2O2/methanol for
15 min. Sections were washed in PBS and blocked with
5% normal goat serum in PBS before overnight incuba-
tion at 4°C with the primary antibody (1:1200) in 5%
blocking serum. The sections were washed, and then
incubated with biotinylated goat anti-rabbit antibody
(Vector Laboratories, Burlingame, CA) for 1 h. Staining
was visualized using the ABC method and 3,3’-diamino-
benzidine and sections were counterstained with hemo-
toxylin. Isotype-matched IgG was used as negative
control. Immunostaining was visualized using an Optro-
nix Microfire camera (model S99808, Goleta, CA)
attached to a Zeiss Axio Imager A.1 microscope (Got-
tingen, Germany). The numbers of Iba1-positive cells
were counted by two blind observers and verified using
ImageJ http://rsbweb.nih.gov/ij/. The number of positive
cells was determined in both hemispheres of a given
section using a total of four sections per mouse and
expressed as number of cells per 100 μm2.
Data Collection and Analysis
Tb and locomotor activity data were collected every
5 min and averaged over 30 minutes. Change in locomotor
activity following injection was calculated as the 30-min
average at each time point minus the 30-min average at
time 0 (the time of injection). Tb and locomotor activity
data from LPS experiments were subjected to repeated-
measures ANOVA in which Time was a within-subjects
measure and MA (MA or Saline) and LPS (LPS or Saline)
were between-subjects measures. Central cytokine mRNA
levels and peripheral cytokines were analyzed using
two-way ANOVA (MA × LPS). When ANOVAs revealed
a significant effect of main factors or main factor interac-
tions, differences in treatment group means were tested
using Fisher’s least-significant differences. All data are pre-
sented as means ± SEM.
Results
MA administration
Figure 1A and 1B shows Tb and changes in locomotor
activity during MA administration. As expected, there
was a main effect of MA for Tb [F (1,30) = 8.022, p <
0.01] and locomotor activity [F (1,30) = 17.27, p <
0.001] whereby MA increased both Tb and locomotor
activity compared to saline.
Methamphetamine administration enhances LPS-induced
fever
We next investigated if MA administration would inter-
fere with the febrile response to a peripheral immune
stimulus (LPS, 100 μg/kg). Mice received four i.p. injec-
tions of MA (5 mg/kg) or saline and then were given i.
p. LPS or saline 24 h after the first MA injection. LPS
induced an increase in Tb that peaked 3-4 h after injec-
tion (Figure 2A). For Tb, there were main effects of LPS
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[F (1,30) = 25.459, p < 0.001] and MA [F (1,30) = 6.139,
p < 0.02]. There was also a trend toward a MA × LPS
interaction (p = 0.06) where animals exposed to MA
had higher fevers in response to LPS than those given
LPS alone. Indeed, the Tb of mice receiving LPS alone
peaked at 1.4°C compared to Tb at time 0 while those
exposed to MA before LPS administration had a peak
fever of 2.2°C.
As expected, there was a main effect of LPS for loco-
motor activity [F (1,30) = 12.012, p < 0.01] where LPS
decreased locomotor activity compared to saline. This
LPS-induced decrease in locomotor activity was not
influenced by prior exposure to MA (Figure 2B).
Methamphetamine administration exacerbates the
neuroinflammatory response to LPS
To examine the neuroinflammatory response to LPS
when mice were actively sick, animals were given four
injections of 5 mg/kg MA or saline, followed by LPS or
saline 24 h after the first MA injection. Mice were killed
at 4 h post-LPS and blood and brains were collected. To
examine the global effects of MA and LPS in the brain,
five regions were collected: the hypothalamus and hip-
pocampus, which are intimately involved in the sickness
response; the striatum and cortex, regions sensitive to
MA; and the cerebellum, a region important for motor
control. Figure 3A, B and 3C shows changes in inflam-
matory cytokine mRNA in the five brain regions studied.
MA alone increased IL-6 mRNA levels in the hypothala-
mus (main effect of MA, p < 0.01) and TNFa mRNA in
the hippocampus and striatum (main effect of MA, p <
0.01 and p < 0.001, respectively). This trend was also
observed in the other regions, although it was not statis-
tically significant. The MA-induced increase in TNFa
mRNA was most apparent in the striatum, where MA
Figure 1 Body temperature and locomotor activity during
methamphetamine administration. Effect of 4 i.p. injections of
MA on Tb (A), and change in locomotor activity (B) Open symbols
represent saline controls and closed symbols represent MA
administration (n = 16-18 per group). Activity data is presented as
30 minute averages from time of injection. Arrows indicate injection
times.
Figure 2 Body temperature and locomotor response to LPS in
mice exposed to methamphetamine. Tb (A) and locomotor
activity (B) after LPS or saline in mice exposed to MA. Mice were
exposed to 4 i.p. injections of 0 or 5 mg/kg MA and then injected
with 100 μg/kg LPS or saline, 24 h after the first MA injection. Open
circles represent saline + saline administration, open triangles
represent saline + MA administration, closed circles represent saline
+ LPS administration and closed triangles represent mice MA + LPS
administration (n = 6-10 per group). Arrow indicates time of
injection; dark bar indicates lights off.
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increased TNFa mRNA levels to the same extent as that
of LPS alone (Figure 3C).
LPS increased inflammatory cytokine mRNA in all
brain regions examined. For IL-1b mRNA (Figure 3A),
there was a MA × LPS interaction whereby MA expo-
sure exacerbated the LPS-induced increase in the
hypothalamus [F (1,12) = 6.545, p < 0.03], hippocampus
[F (1,12) = 7.972, p < 0.02], striatum [F (1,12) = 8.385,
p < 0.02)], cortex [F (1,12) = 8.242, p < 0.02)], and cere-
bellum [F (1,12) = 19.873, p < 0.001]. A similar interac-
tion was seen for IL-6 mRNA (Figure 3B) in the
hypothalamus [F (1,12) = 5.232, p < 0.05], striatum [F
(1,12) = 8.169, p < 0.02], cortex [F (1,12) = 6.946, p <
0.03], and cerebellum [F (1,12) = 4.993, p < 0.05]. The
MA × LPS interaction was also apparent for TNFa
mRNA (Figure 3C) in the hypothalamus [F (1,12) =
Figure 3 Cytokine mRNA expression 4 h after LPS in mice exposed to methamphetamine. IL-1b (A), IL-6 (B), and TNFa (C) mRNA
expression in the hypothalamus, hippocampus, striatum, cortex, and cerebellum in mice exposed to MA. Mice exposed to MA were given LPS or
MA and brains were collected 4 h post-LPS (n = 4 per group). Means with different letters are at least p < 0.05 different from each other.
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6.942, p < 0.03], hippocampus [F (1,12) = 5.14, p <
0.05], cortex [F (1,12) = 5.673, p < 0.04] and cerebellum
[F (1,12) = 9.964, p < 0.01].
Methamphetamine administration increases microglial
expression of Iba1
Based on the results of Thomas and Kuhn (2005), the
MA dosing regimen used here was expected to activate
microglia. We therefore investigated if MA administra-
tion altered the microglial response to LPS. Iba1 is spe-
cifically expressed in microglia and expression is
particularly enhanced under pathological conditions
[27-30]. MA exposure increased Iba1 expression in both
the striatum and the hippocampus (main effect of MA,
p < 0.001). This MA-related increase was also observed
for CD68 mRNA in the hypothalamus, hippocampus,
striatum, and cerebellum (data not shown). Further-
more, while there were main effects for MA and LPS in
both the hippocampus and straitum (Figure 4A and 4B),
there was a MA × LPS interaction in the striatum [F
(1,12) = 5.386, p < 0.05] whereby Iba1 expression was
further increased when MA exposure was paired with
LPS administration.
Methamphetamine influences plasma cytokines
To investigate the peripheral cytokine response to
LPS in MA-exposed mice, blood was collected 4 h post-
LPS and plasma cytokines were measured (Table 1). LPS
increased plasma IL-10 levels regardless of MA exposure
(main effect of LPS, p < 0.01). For IL-1b there was a sig-
nificant MA × LPS interaction whereby MA alone
increased IL-1b while MA plus LPS effectively abolished
the LPS-induced increase [F (1,12) = 10.145, p < 0.01].
A similar MA-related inhibition of the LPS-induced
increase was seen for TNFa but was not statistically sig-
nificant (p = 0.08). The opposite trend was observed for
plasma IL-6. LPS increased IL-6 in both MA-exposed
and non-exposed mice (main effect of LPS, p < 0.01),
but there was a trend towards a MA × LPS interaction
(p = 0.08) where mice exposed to MA had increased
plasma levels of IL-6 than did those given LPS alone.
These data suggest that exposure to MA can alter the
peripheral inflammatory cytokine response to LPS.
Discussion
MA is a popular drug of abuse that has several central
effects and prolonged, or heavy usage can activate the
primary inflammatory cells of the brain; microglia.
Because MA has been shown to heighten the inflamma-
tory environment of the brain, we hypothesized that
MA administration would exacerbate LPS-induced sick-
ness behavior as well as the neuroinflammatory cytokine
response. Using a MA regimen expected to activate
microglia, we demonstrate that MA administration
enhanced LPS-induced fever, and this response was par-
alleled by a dramatic increase in central cytokine mRNA
expression 4 h post-LPS. Moreover, the MA-induced
increase in microglial Iba1 expression was even greater
in mice exposed to both MA and LPS, suggesting that
MA can alter the response of microglia to a subsequent
peripheral immune stimulus.
MA-induced microglial activation has been demon-
strated in animals given high doses of MA [11-13] and
is associated with the production of inflammatory cyto-
kines in the brains of rodents [14-17]. However, little is
known concerning the neuroinflammatory consequences
of such MA use on a subsequent peripheral immune sti-
mulus. We therefore utilized a MA regimen demon-
strated to activate microglia and measured Iba1
expression 4 h after LPS. Microglial Iba1 expression was
significantly increased in animals exposed to MA. While
MA appeared to increase expression of microglial mar-
kers globally, the effect was most apparent in the stria-
tum. Given that MA can greatly affect dopamine nerve
endings in the striatum, the robust MA-related staining
observed in this region is unsurprising. More interest-
ingly, when LPS was given to mice exposed to MA, Iba1
expression was further increased in this region. This
MA-related increase in Iba1 expression was paralleled
by increased expression in inflammatory cytokines in
brain 4 h after LPS. This suggests that the current
model of MA exposure not only activates microglia, but
alters them such that they respond more when the per-
ipheral immune system is stimulated.
MA-related microglial responses appear to depend on
the dose and schedule used. For instance, there are sev-
eral reports demonstrating that chronic low-dose MA
can attenuate the neurotoxic effects of [31-35], and the
microglial response to [13], a subsequent high-dose MA
challenge. Our previous study found that while a single
administration of 1 mg/kg activated microglia, mice
exposed to chronic low-dose MA showed little micro-
glial activation 72 h after the last treatment and
responded minimally when exposed to LPS or an addi-
tional MA injection [26]. This microglial response was
accompanied by an attenuated central inflammatory
cytokine response to LPS. The difference between our
previous results and our current results lies in the MA
dosing regimen; while our previous study was based on
a pharmacological dose, the current study utilized a
neurotoxic dosing schedule. This schedule has been
shown to damage dopamine nerve terminals, promote
glial activation, and increase proinflammatory cytokines
[7,36,37]. Given the dramatic difference between the
two doses and schedules, the difference in the respective
elicited responses is not surprising. While we did
observe MA-associated increases in IL-6 and TNFa
mRNA, these increases (with the exception of TNFa
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Figure 4 Iba1 expression 4 h after LPS in mice exposed to methamphetamine. Immunohistochemical staining of Iba1 in the dentate gyrus
of the hippocampus (A) and the striatum (B) of mice exposed to MA prior to LPS administration at 40× magnification. Mice were exposed to
four i.p. injections of 0 or 5 mg/kg MA at 2 h intervals and then injected with 100 μg/kg LPS or saline 24 h after the first MA injection. Brains
were collected 4 h after LPS administration. Scale bar = 100 μm. Bar graphs express number of Iba1-positive cells per 100 μm2.
Table 1 Plasma cytokines 4 h after LPS in mice exposed to MA
0 mg/kg MA 5 mg/kg MA p
Saline LPS Saline LPS MA LPS MA × LPS
IL-1b 124.63 ± 47.25 253.4 ± 47.48 226.77 ± 10.97 135.57 ± 12.7 0.82 0.59 0.0078#
IL-6 36.61 ± 11.41 662.74 ± 426.8 33.54 ± 9.27 1557.7 ± 196.1 0.08 0.006* 0.08
TNFa 278.61 ± 78.1 501.02 ± 106.5 268.05 ± 33.3 225.49 ± 32.7 0.06 0.22 0.08
IL-10 107.89 ± 28.2 220.43 ± 33.9 111.0 ± 10.57 287.12 ± 69.4 0.42 0.005* 0.46
Mice were given four injections of saline or MA (5 mg/kg) i.p. at 2 h intervals. Twenty-four hours after the first MA injection, mice were given either saline or LPS
(100 μg/kg) and blood was collected at 4 h post-injection. *p < 0.01, different from saline controls. #p < 0.01 MA × LPS interaction.
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mRNA in the striatum) were small. This is most likely
due to the time point of measurement (4 h post-LPS
but 16 h after the first MA administration). Possibly,
had cytokines been measured soon after MA-exposure,
there would have been a MA-related increase. Taken
together, it is possible that MA differentially affects the
microglial response to a peripheral immune stimulus,
either inhibiting or exacerbating the central immune
response depending on the dose and schedule.
Peripheral immune stimulation induces cytokines in
both the brain and the periphery. In the present study,
there was a trend toward MA-related differences in
LPS-induced plasma cytokines, indicating that MA influ-
ences not only the central cytokine response, but the
peripheral response as well. This was particularly true
for IL-1b, in which there was a MA × LPS interaction
whereby MA alone increased IL-1b but also inhibited
the LPS-induced increase in the cytokine. A similar but
not significant effect was observed for plasma TNFa.
This suggests that while MA administration heightened
the central inflammatory response, it concomitantly sup-
pressed the inflammatory cytokine response in the per-
iphery. This differs from our previous study which
showed that, while acute administration of 1 mg/kg MA
increased plasma IL-1b 4 h post-injection, neither acute
nor repeated low-dose MA administration interfered
with the LPS-induced increase in plasma cytokines [26].
As in the case of microglia responses, the difference is
most likely due to differences in the dose and dosing
schedule used. However, the current results are gener-
ally consistent with other reports showing suppressive
effects of MA on peripheral immune function [21,22].
IL-1b is an important cytokine involved in fever. Both
peripheral and central administration of IL-1b induces
fever [38,39] and blocking IL-1b attenuates the fever
response to LPS [40,41]. Given the bidirectional nature
of communication between periphery and brain and the
heightened inflammatory environment of the MA-
exposed brain, it is possible that the MA-related
decrease in LPS-induced IL-1b plasma is an adaptive
mechanism that may serve to downregulate signals from
the periphery in response to the heightened neuroin-
flammatory signals in the CNS. Taken together, our
data suggest that MA alters the production of both
inflammatory and anti-inflammatory cytokines in the
periphery while inducing a heightened inflammatory
environment in the brain.
Peripheral immune stimulation activates brain micro-
glia and LPS reliably induces cytokines in both the brain
and the periphery, but it is this central cytokine
response that is essential for the initiation of sickness
behavior, which is an integrated, adaptive, and protective
response to illness necessary for recovery and survival.
MA use is associated with an increased prevalence of
HIV infection, hepatitis B and C, fungal infections, and
possibly others [1-4]. Given the popularity of MA and
its association with immune dysfunction even years after
MA use has ceased, it is important to understand
how MA influences the immune response. The potential
that MA use can exacerbate the neuroimmune response
to an invading pathogen presents a serious problem in
the human population, since an optimal inflammatory
response is necessary for survival and recovery. Further-
more, because neuroinflammation has been demon-
strated to be an important mechanism involved in a
number of CNS pathologies, it may be possible for MA
abuse to exacerbate or hasten the progression of these
diseases.
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